Darglitazone 是一种噻唑烷二酮，是口服有效的PPAR-γ选择性激动剂。Darglitazone 可以有效控制血糖和脂质代谢，在 II 型糖尿病中有研究价值。

Darglitazone is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism.

In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), Darglitazone(30 μM) stimulated the expression of UCP2 gene probably via PPAR-γ and increased uncoupling protein 2 (UCP2) mRNA[1].

In male diabetic ob/ob mice, Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24?h of recovery. Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[2].

141200-24-0

C23H20N2O4S

420.48

Ethanol:≤5mg/mL
DMSO:20mg/ml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years